GO:0035278 miRNA-mediated gene silencing by inhibition of translation: Translational Repression Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0035278 describes an RNA interference pathway in which microRNAs (miRNAs) incorporated into a RNA-induced silencing complex (RISC) block translation of target mRNAs, typically after imperfect base-pairing with the 3' untranslated region.
• The process is conserved across at least 600 million years of animal evolution, indicating a fundamental role in gene regulation.
• Translational repression is often the first detectable effect, followed by mRNA deadenylation and decay.
• Key protein components include Argonaute (AGO) proteins, GW182 (TNRC6) proteins, and other RISC-associated factors.
• miRNA-mediated silencing influences cancer, viral infection, and neurodevelopment, making it a target for therapeutic intervention.
• CRISPR-based models (knockout, knock-in, overexpression) enable precise dissection of miRNA-mediated translational inhibition in disease contexts.
Description
MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression post-transcriptionally. GO:0035278, miRNA-mediated gene silencing by inhibition of translation, defines a specific RNA interference pathway where miRNAs loaded into a RNA-induced silencing complex (RISC) repress protein synthesis from target mRNAs without necessarily degrading them. This mechanism is critical for fine-tuning gene expression during development, differentiation, and disease. Unlike small interfering RNAs (siRNAs) that typically cleave perfectly matched targets, miRNAs often base-pair imperfectly with the 3' untranslated region (3' UTR) of mRNAs, leading to translational inhibition. This process is highly conserved across animal evolution, underscoring its biological importance. Researchers study GO:0035278 to understand how cells control protein output rapidly and reversibly, and how its dysregulation contributes to cancer, viral pathogenesis, and neurological disorders. The pathway involves multiple steps: miRNA loading into AGO proteins, target recognition, and repression of translation initiation or elongation, sometimes followed by mRNA decay. Experimental approaches such as ribosome profiling, RNA sequencing, and CRISPR-based gene editing are essential to dissect these mechanisms and identify therapeutic targets.
miRNA-mediated gene silencing by inhibition of translation At A Glance
| GO ID | GO:0035278 |
|---|---|
| GO term | miRNA-mediated gene silencing by inhibition of translation |
| Ontology | biological_process |
| Synonym | miRNA-mediated gene silencing; negative regulation of translation involved in gene silencing by microRNA; downregulation of translation involved in gene silencing by miRNA |
| Major function | Repression of protein synthesis via miRNA-guided RISC complex binding to target mRNA 3' UTRs |
| Key components | Argonaute proteins, GW182 (TNRC6), miRNAs, RISC-associated factors |
| Conservation | Conserved across 600 million years of animal evolution |
| Related processes | RNA interference, post-transcriptional gene silencing, mRNA deadenylation and decay |
What Is GO:0035278?
GO:0035278 is a biological process term describing an RNA interference pathway in which microRNAs (miRNAs) block the translation of target mRNAs into proteins. Once incorporated into a RNA-induced silencing complex (RISC), a miRNA typically mediates repression of translation when it imperfectly base-pairs with the 3' untranslated regions of target mRNAs. This definition is based on the QuickGO authoritative annotation.
Why Is miRNA-mediated gene silencing by inhibition of translation Important in Cell Biology?
GO:0035278 is fundamental to understanding how cells regulate protein abundance without altering mRNA levels. This process allows rapid and reversible control of gene expression, which is essential for development, cell cycle progression, and stress responses. Dysregulation of miRNA-mediated translational inhibition is implicated in numerous diseases, including cancer, where miRNAs can act as oncogenes or tumor suppressors, and in viral infections, where viruses encode miRNAs to manipulate host gene expression. Moreover, the pathway is a target for oncolytic virus design and RNA-based therapeutics. Studying this process provides insights into basic gene regulation and offers opportunities for therapeutic intervention.
• Enables fine-tuning of gene expression during development and differentiation.
• Plays a role in cancer biology by modulating oncogene and tumor suppressor expression.
• Involved in viral pathogenesis, including herpesvirus manipulation of miRNA processing.
• Contributes to glioblastoma progression through m6A-dependent regulation of nascent translation.
• Provides a mechanism for rapid cellular responses to environmental changes.
• Conserved across animal evolution, highlighting its fundamental importance.
• Target for oncolytic virus engineering to enhance safety and efficacy.
• Can be studied using CRISPR knockout of AGO proteins to dissect RISC function.
• Impacts mRNA stability and decay pathways, linking translation to transcript turnover.
• Offers potential biomarkers and therapeutic targets in diseases with miRNA dysregulation.
What Happens During miRNA-mediated gene silencing by inhibition of translation?
miRNA Loading into RISC
In simple terms: First, a microRNA is loaded into a protein complex called RISC.
Mature miRNAs are incorporated into the RNA-induced silencing complex (RISC), where they associate with Argonaute (AGO) proteins. This loading step is essential for target recognition and subsequent silencing. The miRNA acts as a guide to direct RISC to complementary sequences in target mRNAs.
Target Recognition via Imperfect Base-Pairing
In simple terms: The miRNA finds its target mRNA by matching sequences, but not perfectly.
The miRNA within RISC typically base-pairs imperfectly with the 3' untranslated region (3' UTR) of target mRNAs. This imperfect complementarity distinguishes miRNA-mediated silencing from siRNA-mediated cleavage and leads to translational repression rather than mRNA degradation.
Inhibition of Translation Initiation
In simple terms: The RISC complex blocks the cell's protein-making machinery from starting translation.
Once bound to the target mRNA, RISC interferes with translation initiation. This can occur through recruitment of decapping factors, inhibition of cap recognition, or blocking of ribosome assembly. The exact mechanism may vary depending on the specific miRNA and cellular context.
Translational Repression Followed by mRNA Deadenylation and Decay
In simple terms: After translation is stopped, the mRNA can be shortened and eventually destroyed.
Translational repression is often the primary effect, but it can be followed by deadenylation of the mRNA poly(A) tail and subsequent decay. This two-step process ensures robust silencing of target genes.
Nuclear Argonaute:miRNA Complexes and Chromatin-Associated RNA Silencing
In simple terms: In the nucleus, similar complexes can also silence genes by interacting with chromatin-associated RNA.
Recent evidence shows that nuclear Argonaute:miRNA complexes can recognize target sequences within chromatin-associated RNA and silence gene expression, expanding the scope of miRNA-mediated silencing beyond the cytoplasm.
Key Genes Involved in GO:0035278 miRNA-mediated gene silencing by inhibition of translation
The following genes and proteins are central to the miRNA-mediated gene silencing by inhibition of translation pathway.
| Gene | Major Role | Research Relevance |
|---|---|---|
| AGO1 | Core component of RISC; binds miRNAs and cleaves or represses target mRNAs | Essential for miRNA function; knockout abolishes silencing |
| AGO2 | Catalytically active Argonaute; mediates slicing and translational repression | Key effector in RNA interference; studied in cancer and viral infection |
| AGO3 | Argonaute family member; involved in piRNA and miRNA pathways | Less characterized; potential roles in germline and stem cells |
| AGO4 | Argonaute protein; functions in nuclear silencing | Implicated in chromatin-associated RNA silencing |
| TNRC6A | GW182 family protein; scaffold for RISC-mediated repression | Recruits deadenylation and decapping factors |
| TNRC6B | GW182 family protein; facilitates translational repression | Modulates miRNA efficacy; knockout affects target repression |
| TNRC6C | GW182 family protein; involved in miRNA silencing | Redundant with other GW182 proteins |
| DICER1 | RNase III enzyme; processes pre-miRNA into mature miRNA | Essential for miRNA biogenesis; mutations in cancer |
| DGCR8 | Microprocessor complex component; binds pri-miRNA | Required for miRNA maturation; knockout impairs silencing |
| XPO5 | Exportin-5; exports pre-miRNA from nucleus | Regulates miRNA availability |
| EIF4AII | Translation initiation factor; dispensable for miRNA silencing | Shows that some initiation factors are not required |
| EIF4E | Cap-binding protein; target of miRNA-mediated repression | Inhibition of EIF4E function blocks translation initiation |
| PABPC1 | Poly(A)-binding protein; interacts with GW182 | Links miRNA silencing to deadenylation |
| CNOT1 | CCR4-NOT complex subunit; mediates deadenylation | Required for mRNA decay following repression |
| MOV10 | RNA helicase; associated with RISC | Modulates miRNA-mediated silencing |
| DDX6 | RNA helicase; involved in translational repression | Recruited by GW182 to repress translation |
| M6A regulators (METTL3, FTO) | Modulate m6A modification; affect miRNA-mediated translation | Linked to glioblastoma and nascent translation |
How Is miRNA-mediated gene silencing by inhibition of translation Regulated?
The miRNA-mediated gene silencing by inhibition of translation pathway is regulated at multiple levels. miRNA biogenesis and availability are controlled by transcription factors, processing enzymes such as DICER1 and DGCR8, and export factors. The activity of RISC can be modulated by post-translational modifications of Argonaute proteins, including phosphorylation and ubiquitination. Additionally, RNA modifications such as m6A can influence miRNA-mediated silencing; for example, miRNA-mediated loss of m6A increases nascent translation in glioblastoma. Viral proteins and miRNAs can also interfere with miRNA processing, as seen with herpesvirus-encoded miRNAs that selectively inhibit miRNA processing. Furthermore, the subcellular localization of Argonaute:miRNA complexes, including nuclear pools, adds another layer of regulation.
miRNA-mediated gene silencing by inhibition of translation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| AGO2 | Cancer, viral infection | Knockout in cancer cell lines; overexpression in primary cells |
| TNRC6A | Cancer, developmental disorders | Knockout and rescue experiments in HEK293 or HeLa |
| DICER1 | Cancer, DICER1 syndrome | Conditional knockout in mouse models; point mutations in cell lines |
| METTL3 | Glioblastoma | Knockout and m6A profiling in glioblastoma cells |
| XPO5 | Cancer, miRNA processing defects | Knockout in cancer cell lines; overexpression studies |
Cancer
Dysregulation of miRNA-mediated translational inhibition is common in cancer. In glioblastoma, miRNA-mediated loss of m6A increases nascent translation, promoting tumor progression. miRNAs can act as tumor suppressors or oncogenes by repressing translation of key cancer-related mRNAs. Targeting this pathway may offer therapeutic strategies.
Viral Infections
Viruses encode miRNAs or manipulate host miRNA machinery to evade immune responses. Herpesviruses, for example, encode miRNAs that selectively inhibit miRNA processing, altering host gene expression. Understanding these interactions can inform antiviral drug development.
Oncolytic Virus Therapy
miRNA-mediated mechanisms are exploited in the design of effective and safe oncolytic viruses. By incorporating miRNA target sites into viral genomes, researchers can restrict viral replication to tumor cells and enhance safety.
Neurological Disorders
miRNA-mediated translational repression is critical for neuronal development and function. Dysregulation has been linked to neurodegeneration, although specific mechanisms remain under investigation.
From miRNA-mediated gene silencing by inhibition of translation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does AGO2 mediate miRNA-dependent translational repression? | AGO2 knockout cell lines (e.g., HCT116) followed by polysome profiling |
| What is the role of TNRC6A in miRNA silencing? | TNRC6A knockout and rescue with wild-type or mutant constructs |
| How does m6A modification affect miRNA-mediated translation? | METTL3 knockout glioblastoma cells with ribosome profiling |
| Can miRNA target sites restrict oncolytic virus replication? | Knock-in of miRNA target sites into viral genome |
| What is the impact of nuclear Argonaute on gene silencing? | Nuclear AGO4 knockout or tagged knock-in |
| Is EIF4AII required for miRNA-mediated silencing? | EIF4AII knockout cells with reporter assays |
How to Study the miRNA-mediated gene silencing by inhibition of translation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Ribo-seq | Translation efficiency and ribosome occupancy | Global analysis of miRNA-mediated translational repression |
| RNA-seq | mRNA abundance and splicing | Distinguish translational inhibition from mRNA decay |
| Proteomics | Protein expression levels | Validate silencing of target proteins |
| Polysome profiling | Distribution of mRNAs across polysomes | Assess translation initiation blockade |
| Luciferase reporter assay | miRNA target site activity | Test specific miRNA-mRNA interactions |
| CLIP-seq | miRNA binding sites on target mRNAs | Identify direct targets of RISC |
| CRISPR knockout | Gene function | Dissect roles of AGO, TNRC6, DICER1 |
| CRISPR knock-in | Tagged protein expression | Study localization and interactions |
Ribosome Profiling (Ribo-seq)
Ribo-seq measures translation efficiency by sequencing ribosome-protected mRNA fragments. It is used to detect changes in translation upon miRNA-mediated silencing and to identify target genes.
RNA Sequencing (RNA-seq)
RNA-seq quantifies mRNA abundance and can reveal changes in transcript levels following miRNA-mediated repression, distinguishing translational inhibition from mRNA decay.
Proteomics
Mass spectrometry-based proteomics measures protein levels and can confirm that miRNA-mediated silencing reduces protein output without affecting mRNA levels.
Imaging and Reporter Assays
Fluorescent reporters containing miRNA target sites in their 3' UTRs are used to visualize translational repression in live cells. This approach enables high-throughput screening for modulators of miRNA activity.
How CRISPR Can Be Used to Study GO:0035278 miRNA-mediated gene silencing by inhibition of translation
Knockout
CRISPR knockout of core components such as AGO2, TNRC6A, or DICER1 abolishes miRNA-mediated silencing, allowing researchers to test the requirement of these genes in specific cellular contexts. Knockout cell lines are valuable for identifying which targets are regulated by this pathway.
Point Mutation
Introducing point mutations in catalytic residues of AGO2 (e.g., D669A) or in miRNA binding pockets can dissect the contribution of slicing versus translational repression. Such models help distinguish between different modes of silencing.
Knock-in
Knock-in of epitope tags (e.g., FLAG, HA) into endogenous AGO or TNRC6 loci enables immunoprecipitation and proteomic studies to identify RISC-associated factors. Tagged knock-in models also allow live-cell imaging of RISC dynamics.
Overexpression
Overexpression of miRNAs or RISC components can enhance silencing and reveal dose-dependent effects. Conversely, overexpression of dominant-negative mutants can inhibit the pathway. These models are useful for studying miRNA function in cancer and viral infection.
How EDITGENE Supports miRNA-mediated gene silencing by inhibition of translation Research
Researchers studying miRNA-mediated gene silencing by inhibition of translation-related genes often need to determine whether a candidate gene is causally involved in the pathway or is merely correlated with changes in gene expression. EDITGENE provides CRISPR-based tools to generate precise knockout, point-mutation, knock-in, and overexpression cell models, enabling rigorous functional validation.
Contact EDITGENE today to design your custom CRISPR model for miRNA-mediated gene silencing by inhibition of translation research.
Frequently Asked Questions About miRNA-mediated gene silencing by inhibition of translation
What is GO:0035278?
GO:0035278 is a Gene Ontology biological process term for miRNA-mediated gene silencing by inhibition of translation, where miRNAs loaded into RISC block translation of target mRNAs.
What genes are involved in miRNA-mediated gene silencing by inhibition of translation?
Key genes include AGO1-4, TNRC6A/B/C, DICER1, DGCR8, XPO5, and EIF4AII, among others.
How does miRNA-mediated translational repression work?
miRNAs guide RISC to imperfectly base-pair with the 3' UTR of target mRNAs, leading to inhibition of translation initiation and sometimes mRNA deadenylation and decay.
What is the difference between miRNA-mediated silencing and siRNA-mediated silencing?
miRNAs typically base-pair imperfectly and repress translation, while siRNAs base-pair perfectly and cleave mRNA.
Is miRNA-mediated gene silencing conserved?
Yes, it is conserved across at least 600 million years of animal evolution.
What diseases are associated with miRNA-mediated gene silencing?
Cancer, viral infections, and neurological disorders are linked to dysregulation of this pathway.
How can CRISPR be used to study miRNA-mediated silencing?
CRISPR knockout, knock-in, and overexpression models allow functional dissection of RISC components and miRNA targets.
What methods are used to measure miRNA-mediated translational repression?
Ribo-seq, RNA-seq, proteomics, polysome profiling, and luciferase reporter assays are commonly used.
What is the role of Argonaute proteins in miRNA silencing?
Argonaute proteins are core components of RISC that bind miRNAs and mediate target recognition and repression.
Can miRNA-mediated silencing be regulated by RNA modifications?
Yes, m6A modification can influence miRNA-mediated silencing, as shown in glioblastoma where miRNA-mediated loss of m6A increases nascent translation.
Conclusion
GO:0035278, miRNA-mediated gene silencing by inhibition of translation, is a fundamental biological process that controls protein synthesis post-transcriptionally. Its conservation across animal evolution and its involvement in cancer, viral infection, and other diseases underscore its importance. Understanding the molecular mechanisms, key genes, and regulatory inputs of this pathway requires robust experimental models. CRISPR-based approaches, combined with advanced profiling methods, provide powerful tools to dissect this process and identify therapeutic targets.
References
- 1. Hennig T et al.. 2022. Selective inhibition of miRNA processing by a herpesvirus-encoded miRNA.. Nature 605(7910):539-544 PMID: 35508655
- 2. Zepecki JP et al.. 2021. miRNA-mediated loss of m6A increases nascent translation in glioblastoma.. PLoS Genet 17(3):e1009086 PMID: 33684100
- 3. Fabian MR et al.. 2012. The mechanics of miRNA-mediated gene silencing: a look under the hood of miRISC.. Nat Struct Mol Biol 19(6):586-93 PMID: 22664986
- 4. Galicia-Vázquez G et al.. 2015. eIF4AII is dispensable for miRNA-mediated gene silencing.. RNA 21(10):1826-33 PMID: 26286746
- 5. Mauri M et al.. 2017. Conservation of miRNA-mediated silencing mechanisms across 600 million years of animal evolution.. Nucleic Acids Res 45(2):938-950 PMID: 27604873
- 6. Djuranovic S et al.. 2012. miRNA-mediated gene silencing by translational repression followed by mRNA deadenylation and decay.. Science 336(6078):237-40 PMID: 22499947
- 7. Hofman CR et al.. 2025. Nuclear Argonaute:miRNA complexes recognize target sequences within chromatin-associated RNA and silence gene expression.. Nucleic Acids Res 53(16) PMID: 40867050
- 8. Toropko M et al.. 2024. miRNA-Mediated Mechanisms in the Generation of Effective and Safe Oncolytic Viruses.. Pharmaceutics 16(8) PMID: 39204331
